TFS Capital’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

TFS Capital’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-19,531	Closed	-$272K	–	1042
2016 Q2	$272K	Sell	19,531 -25,360	-56%	-$373K	0.05%	635
2016 Q1	$681K	Buy	+44,891	New	+$687K	0.1%	366
2015 Q3	–	Sell	-23,960	Closed	-$617K	–	1080
2015 Q2	$617K	Buy	23,960 +5,917	+33%	+$168K	0.06%	461
2015 Q1	$564K	Buy	+18,043	New	+$518K	0.06%	513

Other funds holding PRTK

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

TFS Capital's PRTK Position: Q3 2016 in Review

TFS Capital sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2016, closing a stake of 19,531 shares — an estimated $272K sold.

TFS Capital first reported a position in PRTK in Q1 2015 and held it in 4 quarters. The position peaked at $681K in Q1 2016. 86 funds tracked by Wall St. Rank hold PRTK as of Q3 2016.

TFS Capital reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
TFS Capital sold 19,531 Paratek Pharmaceuticals, Inc. shares in Q3 2016, an estimated $272K.
TFS Capital first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2015 and held it in 4 quarters.
TFS Capital's Paratek Pharmaceuticals, Inc. position peaked at $681K in Q1 2016.
86 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2016.

Based on TFS Capital's 13F filing for Q3 2016, filed 10 Nov 2016.